Abstract:

I shall review this article mainly for its action on blood glucose levels and the cardiovascular system. In this article the author has elaborated only on three drugs namely Sitagliptin, Saxagliptin, and Vildagliptin.

Saxagliptin, Vildagliptin and Sitaglitins are different in their metabolism (Saxagliptin and Vildagliptin are metabolized in the liver while Sitagliptin is not metabolised in liver) their recommended dosage, excretion, and the daily dosage for effective treatment. But when compared to their efficacy regarding lowering the safety of the drug its HBA1c lowering effect and patient tolerance, all are almost same.

I shall look into the different studies which the author has taken as references to impress the usefulness of DPP-4 inhibitors in not only influencing the glycemic cycle but also the cardiovascular system and the weight neutrality.

I shall look into the different studies used as references by the author to prove his point.

A study done by Hsieh et al showed that inhibition of DPP-4, or increasing of GLP-1 receptor (GLP-1R) signaling, causes a decrease dintestinal secretion of triacylglycerol, apolipprotein B-48 and cholesterol. Further the endogenous GLP-1R signaling is required for the control of secretion and biosynthesis of intestinal lipoprotein.

These studies with other similar ongoing studies used by the author have impressed that the DPP-4 inhibitors group of drugs will has a beneficial effect not only on the glycemic control but also on cardiovascular system. 

References:

[1.] Dror, Dicker,M.D.(2011). Impact on glycemic control and cardiovascular risk factors DPP-4 Inhibitors, Diabetes care, volume 34, supplement 2 may 2011. Page:S276 –S278 care.diabetesjournals.org

[2.] Lisa, Nainggolan, (2013). DPP-4 Inhibitors and Heart Failure in Diabetes: Be Vigilant,http://www.medscape.com/viewarticle/817543

[3.] Sell, Henrike, et al titled(2013): Adipose Dipeptidyl Peptidase-4 and Obesity, Diabetes Care Issue: Volume 36(12), , p 4083–4090, care.diabetesjournals.org